NBIX at a glance
Neurocrine Biosciences Inc (NBIX, SEC CIK 914475) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neurocrine Biosciences Inc (NBIX) reported revenue of $2.9 billion (up 21.4% from FY2024) and net income of $478.6 million. Diluted EPS was $4.67.
- As of September 30, 2026, 37 institutional investment managers tracked by SignalX reported holding Neurocrine Biosciences Inc (NBIX) shares worth $7.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by LYONS GARY A on November 17, 2026 of 1,200 shares at $163.11 per share.
- In the last 90 days, NBIX insiders reported 0 open-market purchases ($0) and 19 open-market sales ($5.6M) on Form 4, a net sale of $5.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.9B
- +21.4% vs prior year
- Insiders · 90 days
- 0 buys · 19 sells
- Net −$5.6M
- 13F holders
- 37 funds
- $7.1B · −1 vs prior quarter
- Latest 8-K
- Nov 2, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Third-quarter revenue $1,122.7M, up $327.8M YoY from $794.9M
- Operating margin 29.5% vs 30.1% YoY, net margin 18.4% vs 26.4%
- Best product: INGREZZA sales $801.5M vs $686.6M; worst: Other sales $0 vs $5.2M
- Cash, equivalents and securities $789.7M vs $2,543.4M; operating cash flow $677.4M for nine months
- Soleno acquisition consumed $2.4B cash; $1.0B credit capacity available, funding sufficient for at least 12 months
Risk Factors
- Newly added risk: VYKAT XR safety scrutiny, August 2026 advocacy warnings followed serious adverse-event reports to FDA’s AEMS
- Most materially updated regulatory risk: FDA identified fluid retention as a potential VYKAT XR safety signal in September 2026
- Legal and compliance risk: DOJ civil investigative demand seeks INGREZZA sales and marketing documents, received August 2025
- Operational risk: four distribution customers represent over 90% of gross product sales, concentrating revenue exposure
- Financial risk: $1.0 billion secured revolver entered May 2026, with variable-rate borrowings and quarterly leverage covenants
AI summary of the NBIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Full financial results and management commentary provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.123B, up 41% year over year, with net product sales exceeding $1B for the first time
- INGREZZA sales $801M, up 17%; 2026 guidance raised to $2.9B-$2.925B
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CMO transition effective September 28, 2026: Eiry W. Roberts succeeds Sanjay Keswani
- Keswani’s departure was mutually agreed, with severance eligibility under the Executive Severance Plan
Item EX-99.1: Item EX-99.1
- Soleno acquisition closed May 18, 2026 at $53.00 per share, adding VYKAT XR for Prader-Willi syndrome
- Pro forma revenue $3,050.9M in 2025, including $190.4M from Soleno
AI summaries of NBIX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NBIX
Don't miss the next NBIX filing
- Alerts as it files. A push when NBIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NBIX, by share count.
- Ask anything. An AI agent that reads every NBIX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LYONS GARY A | M | Nov 17, 2026 | 15,000 | $53.64 |
| LYONS GARY A | Sell | Nov 17, 2026 | 1,200 | $163.11 |
| LYONS GARY A | Sell | Nov 17, 2026 | 5,689 | $165.15 |
| LYONS GARY A | Sell | Nov 17, 2026 | 4,011 | $163.94 |
| LYONS GARY A | Sell | Nov 17, 2026 | 4,100 | $165.90 |
| LYONS GARY A | M | Nov 17, 2026 | 15,000 | - |
| ROBERTS EIRY | A | Nov 4, 2026 | 1,506 | - |
| ROBERTS EIRY | A | Nov 4, 2026 | 8,314 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4B | $2.9B |
| Operating Income | - | $570.5M | $619.1M |
| Net Income | $249.7M | $341.3M | $478.6M |
| Op. Margin | - | 24.2% | 21.6% |
| Net Margin | - | 14.5% | 16.7% |
| Balance Sheet | |||
| Total Assets | $3.3B | $3.7B | $4.6B |
| Equity | - | $2.6B | $3.3B |
| ROE | - | 13.2% | 14.7% |
| Per Share | |||
| EPS | $2.47 | $3.29 | $4.67 |
| Cash Flow | |||
| Operating CF | - | $595.4M | $782.7M |
| CapEx | $28.3M | $38.2M | $34.0M |
Source: XBRL data in Neurocrine Biosciences Inc (NBIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NBIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 37 | $7.10B |
| Q2 2026 | 38 | $8.79B |
| Q1 2026 | 39 | $6.90B |
| Q4 2025 | 36 | $6.85B |
| Q3 2025 | 37 | $7.76B |
| Q2 2025 | 34 | $6.39B |
| Q1 2025 | 37 | $3.47B |
| Q4 2024 | 33 | $4.00B |
- BlackRock+1.14M (+8%)
- State Street Corp+422.4K (+10%)
- Millennium Management+357.3K (+3084%)
- Morgan Stanley+125.3K (+10%)
- Bank of America Corp+122.4K (+20%)
- Two Sigma Investments−2.00M (-96%)
- JPMorgan Chase & Co−1.11M (-17%)
- AQR Capital Management−755.7K (-20%)
- Goldman Sachs Group−363.8K (-58%)
- Prudential Financial−87.5K (-49%)
- Marex Group plc+5.0K
- FMR LLC (Fidelity)−314.0K
- CITY HOLDING CO−100
Source: 13F-HR filings on SEC EDGAR (aggregated from 291 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NBIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
NBIX SEC filings: frequently asked questions
Are NBIX insiders buying or selling?
In the last 90 days, Neurocrine Biosciences Inc (NBIX) officers, directors and 10% owners reported no open-market purchases and 19 open-market sales worth $5.6 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NBIX stock?
As of September 30, 2026, the largest Neurocrine Biosciences Inc (NBIX) holders among the 13F filers tracked by SignalX were BlackRock ($2.1 billion), JPMorgan Chase & Co ($733.0 million), Vanguard Portfolio Management LLC ($717.7 million), State Street Corp ($682.0 million), Vanguard Capital Management LLC ($649.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NBIX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neurocrine Biosciences Inc (NBIX) reported revenue of $2.9 billion (up 21.4% from FY2024) and net income of $478.6 million. Diluted EPS was $4.67. The figures come from the XBRL data in the 10-K.
What did NBIX report in its latest 8-K?
Neurocrine Biosciences Inc (NBIX) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results announced for quarter ended September 30, 2026.
What are the latest NBIX SEC filings?
Neurocrine Biosciences Inc (NBIX) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 19, 2026.
What is NBIX's SEC CIK number?
Neurocrine Biosciences Inc (NBIX)'s SEC Central Index Key (CIK) is 914475. EDGAR lists every NBIX filing under that number.
Ask anything about NBIX
The research agent reads NBIX's filings, financials, insider trades and 13F holders, then answers with sources.